Emerging roles of PPARδ in metabolism

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 9, 2007, Pages 1125-1131

  Seedorf, Udo ^a   Aberle, Jens ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Diabetes type 2; Dyslipidemia; HDL cholesterol; Insulin resistance; Metabolic syndrome; Obesity; Peroxisome proliferator activated receptor

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CARBACYCLIN; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSATETRAENOIC ACID; ILOPROST; INSULIN; LIGAND; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHYTANIC ACID; PIRINIXIC ACID; PROSTAGLANDIN A1; VALPROIC ACID; ISOENZYME;

ATHEROSCLEROSIS; BINDING AFFINITY; BODY MASS; CARCINOGENESIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DEVELOPMENTAL BIOLOGY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GENETIC RISK; GLUCOSE TOLERANCE; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOMODULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE POLYP; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER; MACROPHAGE; METABOLIC SYNDROME X; METABOLISM; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; UPREGULATION; ENERGY METABOLISM; ENZYME ACTIVATION; GENETICS;

ENERGY METABOLISM; ENZYME ACTIVATION; HUMANS; ISOENZYMES; METABOLIC SYNDROME X; POLYMORPHISM, GENETIC; PPAR DELTA;

EID: 34548635236     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.04.017     Document Type: Review

References (53)

1. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28 (2005) 1769-1778
3. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
4. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., Hayflick L., Butler R.N., Allison D.B., and Ludwig D.S. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352 (2005) 1138-1145
5. Privalsky M.L. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66 (2004) 315-360
6. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
7. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
8. Corton J.C., Lapinskas P.J., and Gonzalez F.J. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat. Res. 448 (2000) 139-151
9. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
10. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 116 (2006) 581-589
11. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
12. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., and Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6 (1992) 1634-1641
13. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
14. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., and Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7355-7359
15. Peters J.M., Lee S.S., Li W., Ward J.M., Gavrilova O., Everett C., Reitman M.L., Hudson L.D., and Gonzalez F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20 (2000) 5119-5128
16. Tan N.S., Michalik L., Noy N., Yasmin R., Pacot C., Heim M., Fluhmann B., Desvergne B., and Wahli W. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15 (2001) 3263-3277
17. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., and Evans R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 303-308
18. Barish G.D., Narkar V.A., and Evans R.M. PPARδ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116 (2006) 590-597
19. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137 (1996) 354-366
20. Pette D., and Staron R.S. Myosin isoforms, muscle fiber types, and transitions. Microsc. Res. Tech. 50 (2000) 500-509
21. He J., Watkins S., and Kelley D.E. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50 (2001) 817-823
22. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137 (1996) 354-366
23. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., and Evans R.M. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2 (2004) e294
24. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., and Grimaldi P.A. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17 (2003) 2299-2301
25. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15924-15929
26. Abbot E.L., McCormack J.G., Reynet C., Hassall D.G., Buchan K.W., and Yeaman S.J. Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. FEBS J. 272 (2005) 3004-3014
27. Solanes G., Pedraza N., Iglesias R., Giralt M., and Villarroya F. Functional relationship between MyoD and peroxisome proliferator-activated receptor-dependent regulatory pathways in the control of the human uncoupling protein-3 gene transcription. Mol. Endocrinol. 17 (2003) 1944-1958
28. Tall A. Plasma lipid transfer proteins. Annu. Rev. Biochem. 64 (1995) 235-257
29. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., and Evans R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 (2003) 159-170
30. Kramer D.K., Al-Khalili L., Perrini S., Skogsberg J., Wretenberg P., Kannisto K., Wallberg-Henriksson H., Ehrenborg E., Zierath J.R., and Krook A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes 54 (2005) 1157-1163
31. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., and Evans R.M. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3444-3449
32. Kharroubi I., Lee C.H., Hekerman P., Darville M.I., Evans R.M., Eizirik D.L., and Cnop M. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 49 (2006) 2350-2358
33. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5306-5311
34. Vosper H., Patel L., Graham T.L., Khoudoli G.A., Hill A., Macphee C.H., Pinto I., Smith S.A., Suckling K.E., Wolf C.R., and Palmer C.N. The peroxisome proliferator-activated receptor ( promotes lipid accumulation in human macrophages. J. Biol. Chem. 276 (2001) 44258-44265
35. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
36. Chawla A., Lee C.H., Barak Y., He W., Rosenfeld J., Liao D., Han J., Kang H., and Evans R.M. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1268-1273
37. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114 (2004) 1538-1540
38. Lee C.H., Kang K., Mehl I.R., Nofsinger R., Alaynick W.A., Chong L.W., Rosenfeld J.M., and Evans R.M. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2434-2439
39. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., Evans R.M., Schneider M.D., Brako F.A., Xiao Y., Chen Y.E., and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10 (2004) 1245-1250
40. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., Sternbach D.D., Lehmann J.M., Wisely G.B., Willson T.M., Kliewer S.A., and Milburn M.V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3 (1999) 397-403
41. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4312-4317
42. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., Brown M., and Lazar M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270 (1995) 23975-23983
43. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997) 779-791
44. Leibowitz M.D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C.A., Sparrow C.P., Baffic J., Berger G.D., Santini C., Marquis R.W., Tolman R.L., Smith R.G., Moller D.E., and Auwerx J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473 (2000) 333-336
45. van der Veen J.N., Kruit J.K., Havinga R., Baller J.F., Chimini G., Lestavel S., Staels B., Groot P.H., Groen A.K., and Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46 (2005) 526-534
46. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 10 (2004) 245-247
47. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., and DuBois R.N. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19069-19074
48. Skogsberg J., Kannisto R., Roshani L., Gagne E., Hamsten A., Larsson C., and Ehrenborg E. Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int. J. Mol. Med. 6 (2000) 73-81
49. Skogsberg J., McMahon A.D., Karpe F., Hamsten A., Packard C.J., and Ehrenborg E. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J. Intern. Med. 254 (2003) 597-604
50. Aberle J., Hopfer I., Beil F.U., and Seedorf U. Association of the T + 294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int. J. Med. Sci. 3 (2006) 108-111
51. Chen S., Tsybouleva N., Ballantyne C.M., Gotto A.M., and Marian A.J. Effects of PPARα, γ and δ haplotypes on plasma levels of lipids and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14 (2004) 61-71
52. Robitaille J., Gaudet D., Perusse L., and Vohl M.C. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta-87T > C polymorphism and dietary fat in French-Canadians. Int. J. Obes. (Lond) 31 (2007) 411-417
53. Andrulionyte L., Peltola P., Chiasson J.L., and Laakso M. STOP-NIDDM Study Group, Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 55 (2006) 2148-2152